Key Considerations Before Investing in TMO

By Harris Dyer • Monday, June 30 15:21 • Permanent Link

Large-cap Industrials company Thermo Fisher Scientific Inc has moved -0.8% so far today on a volume of 2,229,596, compared to its average of 2,840,188. In contrast, the S&P 500 index moved 0.0%.

Thermo Fisher Scientific Inc trades -26.95% away from its average analyst target price of $554.49 per share. The 27 analysts following the stock have set target prices ranging from $450.0 to $767.0, and on average have given Thermo Fisher Scientific Inc a rating of buy.

Anyone interested in buying TMO should be aware of the facts below:

Thermo Fisher Scientific Inc's current price is 84.6% above its Graham number of $219.43, which implies that at its current valuation it does not offer a margin of safety
Thermo Fisher Scientific Inc has moved -24.6% over the last year, and the S&P 500 logged a change of 12.7%
Based on its trailing earnings per share of 17.07, Thermo Fisher Scientific Inc has a trailing 12 month Price to Earnings (P/E) ratio of 23.7 while the S&P 500 average is 29.3
TMO has a forward P/E ratio of 17.2 based on its forward 12 month price to earnings (EPS) of $23.49 per share
Its Price to Book (P/B) ratio is 3.1 compared to its sector average of 2.89
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.
Based in Waltham, the company has 125,000 full time employees and a market cap of $152.89 Billion. Thermo Fisher Scientific Inc currently returns an annual dividend yield of 0.4%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.